Ge Long Hui·2025-11-11 02:56Core Viewpoint - The A-share market is experiencing a strong performance in flu-related stocks, driven by expectations of a flu outbreak in the upcoming winter season [1] Group 1: Market Performance - Flu concept stocks in the A-share market have shown significant gains, with Te Yi Pharmaceutical hitting the daily limit, Tai Long Pharmaceutical and Nanxin Pharmaceutical rising over 7%, Weikang Pharmaceutical increasing over 5%, and Peking University Pharmaceutical up nearly 4% [1] - Yiling Pharmaceutical has also seen an increase of almost 4% [1] Group 2: Health Forecast - The China Center for Disease Control and Prevention (CDC) predicts that the peak of the flu epidemic in China this autumn and winter may occur in mid-December to early January [1] - The CDC is actively monitoring and assessing flu activity across the country, indicating that the overall flu activity in China is currently on the rise [1] - The H3N2 subtype of the influenza virus accounts for over 95% of the cases, with a small presence of H1N1 and B-type influenza viruses circulating simultaneously [1]